Is Zai Lab Ltd (ZLAB) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 10.4% / 30% | 31.9% / 30% | 5.5% / 30% | 7.18% / 5% | ✗ NOT HALAL |
| DJIM | 10.4% / 33% | 31.9% / 33% | 5.5% / 33% | 7.18% / 5% | ✗ NOT HALAL |
| MSCI | 19.1% / 33% | 58.8% / 33% | 10.1% / 33% | 7.18% / 5% | ✗ NOT HALAL |
| S&P | 10.4% / 33% | 31.9% / 33% | 5.5% / 33% | 7.18% / 5% | ✗ NOT HALAL |
| FTSE | 19.1% / 33% | 58.8% / 33% | 10.1% / 50% | 7.18% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 10.5% | |
| Operating Margin | -54.4% | |
| Net Margin | -38.1% | |
| Return on Equity (ROE) | -22.6% | |
| Return on Assets (ROA) | -12.2% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$151M |
| Free Cash Flow | -$164M |
| Total Debt | $224M |
| Debt-to-Equity | 31.3 |
| Current Ratio | 2.4 |
| Total Assets | $1.2B |
Price & Trading
| Last Close | $17.51 |
| 50-Day MA | $18.55 |
| 200-Day MA | $26.43 |
| Avg Volume | 718K |
| Beta | 0.9 |
|
52-Week Range
$15.96
| |
About Zai Lab Ltd (ZLAB)
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. Zai Lab Limited has license and collaboration agreements with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure Ltd. to develop and commercialize Tumor Treating Fields; Deciphera Pharmaceuticals, LLC to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx BV to develop and commercialize efgartigimod; Turning Point Therapeutics, Inc. to develop and commercialize products containing repotrectinib; Entasis Therapeutics Holdings Inc. to develop and commercialize Durlobactam with Sulbactam; and Karuna Therapeutics, Inc. to develop and commercialize Xanomeline and trospium chloride, as well as strategic collaboration with Pfizer Inc. for Tisotumab Vedotin. The company was incorporated in 2013 and is based in Pudong, China.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Zai Lab Ltd (ZLAB) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Zai Lab Ltd is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Zai Lab Ltd's debt ratio?
Zai Lab Ltd's debt ratio is 10.4% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 19.1%.
What are Zai Lab Ltd's key financial metrics?
Zai Lab Ltd has a market capitalization of $2.0B, and revenue of $460M. The company maintains a gross margin of 10.5% and a net margin of -38.1%. Return on equity stands at -22.6%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.